Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Dohner

Phlebology Walton, NY Medical Doctor

NPI 1801869821 CMS profile 308455

6 Franklin Rd, Walton, NY 13856

Open in the dashboard

General payments

$3,707

133 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Dohner of Walton, NY is reported in the CMS Open Payments database as having received $3,707 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Phlebology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $529 16
2024 General $439 21
2023 General $586 20
2022 General $381 14
2021 General $518 12
2020 General $193 7
2019 General $1,061 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Dohner
  • Phlebology median
  • Middle half of Phlebology
  • National median

In program year 2025, general payments to Eric Dohner were reported at $529. Among 79 Phlebology profiles paid that year, the median was $146 and the middle half received between $41 and $404.

Show as a table
Year Eric Dohner Phlebology median Middle half National median
2019 $1,061 $184 $47–$602 $163
2020 $193 $129 $64–$375 $114
2021 $518 $144 $48–$585 $132
2022 $381 $171 $46–$575 $149
2023 $586 $207 $37–$633 $160
2024 $439 $175 $53–$445 $164
2025 $529 $146 $41–$404 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $969 46 payments
  2. Merz North America, Inc. $661 5 payments
  3. Lilly USA, LLC $306 12 payments
  4. Sun Pharmaceutical Industries Inc. $277 8 payments
  5. Incyte Corporation $226 2 payments
  6. Genzyme Corporation $191 9 payments
  7. Janssen Biotech, Inc. $168 6 payments
  8. Janssen Scientific Affairs, LLC $117 1 payment
  9. Pfizer Inc. $111 6 payments
  10. Allergan Inc. $106 6 payments
  11. Other $575 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,707 133 payments
Products named General payments · program years 2019–2025
  1. Xeomin $522 4 payments
  2. HUMIRA $387 20 payments
  3. ILUMYA $277 8 payments
  4. DUPIXENT $253 12 payments
  5. TREMFYA $237 5 payments
  6. OPZELURA $226 2 payments
  7. SKYRIZI $222 15 payments
  8. TALTZ $193 10 payments
  9. RINVOQ $147 2 payments
  10. STELARA $111 3 payments
  11. Other $1,206 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

109

Median for Family Practice: 1,826

Drug cost

$12,427

Median for Family Practice: $120,094

Branded share of claims

51.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 13 $8,288
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 21 $3,858
Valacyclovir Valacyclovir Hcl Brand 22 $107
Naproxen Generic 24 $98
Tramadol Hcl Generic 18 $58
Amoxicillin Generic 11 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$82,897

Medicare's payments for the services billed

Medicare patients

116

Average age 74

Services billed

544

79 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 47%
Diabetes 18%
Atrial fibrillation 15%
Depression 14%
Heart failure 13%
Chronic kidney disease 13%
Osteoporosis 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
  • Sun Pharmaceutical Industries Inc. $98
$98 — —
SKYRIZI
  • AbbVie, Inc. $84
$84 — —
DUPIXENT
  • GENZYME CORPORATION $59
$59 — —
TALTZ
  • Lilly USA, LLC $35
$35 — —
RINVOQ
  • AbbVie, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Phlebology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record